CSL Ltd (ASX: CSL) Share Price and News

Price

$274.57

Movement

0.00 (0.0)

as at 21 Jan - Closed (20 mins delayed)

52 Week Range

$265.14 - $313.55

 
1 Year Return

-5.49%

CSL Ltd Chart and Price Data

2025
2025
2025
2025
$250
$300
$350
$250
$300
$350
$250
$300
$350
$250
$300
$350

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $132.95 billion
P/E Ratio 31.47
Dividend Yield 1.44%
Shares Outstanding 484.21 million
Earnings per share 5.450
Dividend per share 3.97
Year To Date Return -2.32%
Earnings Yield 3.18%
Franking -
Share Price

$274.57

Day Change

0.00 (0.0)

52 Week Range

$265.14 - $313.55

Yesterday's Close

$274.57

Today's Open

Days Range

-

Volume

0

Avg. Volume (1 month)

437,452

Turnover

$0

as at 21 Jan - Closed

CSL Ltd (ASX: CSL)
Latest News

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
How to invest

My ASX share portfolio is up 40% in 2024! Here's my strategy for 2025

Investing in quality companies paid off in 2024. Here's what I did.

Read more »

A young couple hug each other and smile at the camera standing in front of their brand new luxury car
Retirement

How I'd generate $80,000 of retirement income from ASX shares

This is one way that investors could aim for a rich retirement.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter names the best ASX 200 shares to buy in 2025

These shares have been given a big thumbs up by the broker ahead of the new year.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Should I buy CSL shares today?

With CSL’s valuation improving, is the ASX 200 biotech stock one to buy today?

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

3 excellent ASX 200 blue chip shares to buy in 2025

Analysts have good things to say about these blue chips.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

Smiling elderly couple looking at their superannuation account, symbolising retirement.
Retirement

3 ASX 200 retirement shares that could be top buys in 2025

Analysts think these shares could be good options for a retirement portfolio. Let's see why.

Read more »

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

What's the diagnosis for ASX healthcare shares in 2025?

Do we have a healthy future in store?

Read more »

ResMed share price healthcare asx share price flat represented by doctor shrugging
Healthcare Shares

Will the CSL share price beat the market in 2025?

Let's see what analysts are predicting for this biotechnology giant next year.

Read more »

a happy young woman holding multiple shopping bags
Cheap Shares

Top ASX shares to buy on discount in December 2024

Black Friday may be over but there are still bargains to be found on the ASX!

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

2 ASX healthcare shares that are screaming buys in December

These might go on the Christmas list.

Read more »

Frequently Asked Questions

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
09 Sep 2024 $2.1746 0.00% Final 02 Oct 2024
11 Mar 2024 $1.7989 0.00% Interim 03 Apr 2024
11 Sep 2023 $2.0078 6.42% Final 04 Oct 2023
09 Mar 2023 $1.6215 0.00% Interim 05 Apr 2023
06 Sep 2022 $1.7583 10.00% Final 05 Oct 2022
07 Mar 2022 $1.4229 0.00% Interim 06 Apr 2022
02 Sep 2021 $1.5897 10.00% Final 30 Sep 2021
04 Mar 2021 $1.3491 0.00% Interim 01 Apr 2021
10 Sep 2020 $1.4696 0.00% Final 09 Oct 2020
11 Mar 2020 $1.4713 0.00% Interim 09 Apr 2020
10 Sep 2019 $1.4545 0.00% Final 11 Oct 2019
13 Mar 2019 $1.2032 0.00% Interim 12 Apr 2019
11 Sep 2018 $1.2782 0.00% Final 12 Oct 2018
14 Mar 2018 $1.0050 0.00% Interim 13 Apr 2018
12 Sep 2017 $0.0000 0.00% Final 13 Oct 2017
15 Mar 2017 $0.8378 0.00% Interim 13 Apr 2017
13 Sep 2016 $0.8867 0.00% Final 07 Oct 2016
23 Mar 2016 $0.8147 0.00% Interim 15 Apr 2016
07 Sep 2015 $0.8999 0.00% Final 02 Oct 2015
16 Mar 2015 $0.7439 0.00% Interim 10 Apr 2015
08 Sep 2014 $0.6485 0.00% Final 03 Oct 2014
05 Mar 2014 $0.5888 0.00% Interim 04 Apr 2014
09 Sep 2013 $0.5698 0.00% Final 04 Oct 2013
05 Mar 2013 $0.3406 0.00% Interim 05 Apr 2013
17 Sep 2012 $0.3290 0.00% Final 12 Oct 2012
14 Mar 2012 $0.2520 0.00% Interim 13 Apr 2012
19 Sep 2011 $0.3210 6.23% Final 14 Oct 2011
08 Mar 2011 $0.2450 0.00% Interim 08 Apr 2011
13 Sep 2010 $0.3308 15.96% Final 08 Oct 2010
09 Mar 2010 $0.2450 0.00% Interim 09 Apr 2010
14 Sep 2009 $0.2800 0.00% Final 09 Oct 2009
17 Sep 2007 $0.4675 58.82% Final 12 Oct 2007
14 Mar 2006 $0.1960 0.00% Interim 13 Apr 2006
30 Aug 2005 $0.0753 23.64% Special 10 Oct 2005
30 Aug 2005 $0.3000 100.00% Final 10 Oct 2005
29 Mar 2004 $0.1200 100.00% Interim 13 Apr 2004

CSL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
14th Jan 2025 2025-01-14T09:56:56 Notification of cessation of securities - CSLYesNo9:56am413k
19th Dec 2024 2024-12-19T08:11:48 Change in substantial holdingYesNo8:11am1242.9M
9th Dec 2024 2024-12-09T14:09:37 Notification of cessation of securities - CSLYesNo2:09pm413k
5th Dec 2024 2024-12-05T15:55:36 Notification regarding unquoted securities - CSLYesNo3:55pm515k
5th Dec 2024 2024-12-05T15:44:31 Initial Director's Interest NoticeYesNo3:44pm2127k
3rd Dec 2024 2024-12-03T13:28:02 Application for quotation of securities - CSLYesNo1:28pm616k
7th Nov 2024 2024-11-07T11:51:18 Notification of cessation of securities - CSLYesNo11:51am413k
5th Nov 2024 2024-11-05T12:33:55 Change of Director's Interest NoticeYesNo12:33pm4355k
5th Nov 2024 2024-11-05T12:32:10 Notification regarding unquoted securities - CSLYesNo12:32pm617k
4th Nov 2024 2024-11-04T11:51:38 Notification of cessation of securities - CSLYesNo11:51am413k

About CSL Ltd

CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.

CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.

CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).

The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.

 

CSL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Jan 2025 $275.06 $-0.55 -0.20% 950,508 $278.35 $278.53 $274.35
16 Jan 2025 $275.61 $-0.72 -0.26% 733,643 $279.26 $279.49 $275.27
15 Jan 2025 $276.33 $-3.31 -1.18% 485,779 $278.09 $279.31 $275.76
14 Jan 2025 $279.64 $-0.36 -0.13% 426,575 $281.69 $282.00 $278.75
13 Jan 2025 $280.00 $-5.09 -1.79% 604,880 $279.39 $280.46 $278.14
10 Jan 2025 $285.09 $-2.46 -0.86% 396,813 $287.46 $287.98 $283.94
09 Jan 2025 $287.55 $-0.78 -0.27% 405,762 $288.30 $289.20 $286.40
08 Jan 2025 $288.33 $2.63 0.92% 613,130 $288.03 $290.32 $286.80
07 Jan 2025 $285.70 $1.39 0.49% 373,136 $285.00 $287.35 $284.50
06 Jan 2025 $284.31 $0.88 0.31% 375,381 $283.50 $285.38 $282.84
03 Jan 2025 $283.43 $2.25 0.80% 425,862 $283.23 $284.13 $280.26
02 Jan 2025 $281.18 $-0.40 -0.14% 225,009 $280.56 $282.04 $279.43
31 Dec 2024 $281.58 $-1.49 -0.53% 210,673 $281.66 $282.86 $280.59
30 Dec 2024 $283.07 $0.72 0.26% 292,649 $283.29 $283.43 $280.56
27 Dec 2024 $282.35 $1.60 0.57% 289,051 $283.65 $283.70 $280.73
24 Dec 2024 $280.75 $2.64 0.95% 195,649 $280.18 $281.74 $279.72
23 Dec 2024 $278.11 $1.54 0.56% 338,993 $278.10 $278.65 $276.24

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
31 Oct 2024 Paul McKenzie Sell 4,000 $1,148,600
On-market trade.
30 Oct 2024 Paul McKenzie Issued 38,065 $10,942,164
Issue of securities. 103,522 Performance Share Units
03 Sep 2024 Paul McKenzie Sell 3,779 $1,149,997
On-market trade.
03 Sep 2024 Paul McKenzie Expiry 10,742 $3,287,374
As advised by the company. Lapsed, 73,732 Rights
03 Sep 2024 Paul McKenzie Buy 8,275 $2,532,398
Conversion of securities.
03 Sep 2024 Paul McKenzie Exercise 8,275 $2,532,398
Conversion of securities. 65,457 Rights
21 Aug 2024 Megan Clark Issued 264 $80,277
Director remuneration. vwap, 264 Rights
21 Aug 2024 Brian McNamee Issued 625 $190,050
Director remuneration. vwap, 625 Rights
21 Aug 2024 Samantha (Sam) Lewis Issued 220 $66,897
Director remuneration. vwap, 220 Rights
21 Aug 2024 Duncan Maskell Issued 220 $66,897
Director remuneration. vwap, 220 rights
21 Aug 2024 Robert Cuthbertson Issued 264 $80,277
Director remuneration. 264 Rights, vwap
21 Aug 2024 Carolyn Hewson Issued 352 $107,036
Director remuneration. vwap, 352 rights
21 Aug 2024 Marie McDonald Issued 176 $53,518
Director remuneration. 176 Rights, vwap
21 Aug 2024 Alison Watkins Issued 308 $93,656
Director remuneration. VWAP, 308 Rights
16 Aug 2024 Carolyn Hewson Buy 193 $58,930
Conversion of securities.
16 Aug 2024 Megan Clark Buy 145 $44,274
Conversion of securities.
16 Aug 2024 Robert Cuthbertson Exercise 145 $44,274
Conversion of securities.
16 Aug 2024 Duncan Maskell Exercise 338 $103,204
Conversion of securities.
16 Aug 2024 Samantha (Sam) Lewis Exercise 114 $34,808
Conversion of securities.
16 Aug 2024 Marie McDonald Exercise 145 $44,274
Conversion of securities.
16 Aug 2024 Brian McNamee Buy 343 $104,731
Conversion of securities.
16 Aug 2024 Marie McDonald Buy 145 $44,274
Conversion of securities.
16 Aug 2024 Carolyn Hewson Exercise 193 $58,930
Conversion of securities.
16 Aug 2024 Alison Watkins Exercise 169 $51,602
Conversion of securities.
16 Aug 2024 Robert Cuthbertson Buy 145 $44,274
Conversion of securities.
16 Aug 2024 Duncan Maskell Buy 338 $103,204
Conversion of securities.
16 Aug 2024 Alison Watkins Buy 169 $51,602
Conversion of securities.
16 Aug 2024 Samantha (Sam) Lewis Buy 114 $34,808
Conversion of securities.
16 Aug 2024 Megan Clark Exercise 145 $44,274
Conversion of securities.
16 Aug 2024 Brian McNamee Exercise 343 $104,731
Conversion of securities.
21 Feb 2024 Samantha (Sam) Lewis Issued 114 $32,190
Director remuneration. VWAP
16 Feb 2024 Megan Clark Buy 145 $41,180
Conversion of securities.
16 Feb 2024 Alison Watkins Buy 169 $47,996
Conversion of securities.
16 Feb 2024 Marie McDonald Exercise 145 $41,180
Conversion of securities. 145 Right
16 Feb 2024 Carolyn Hewson Buy 193 $54,812
Conversion of securities.
16 Feb 2024 Duncan Maskell Exercise 339 $96,276
Conversion of securities. 338 Rights
16 Feb 2024 Robert Cuthbertson Exercise 145 $41,180
Conversion of securities. 145 Rights
16 Feb 2024 Brian McNamee Buy 343 $97,412
Conversion of securities.
16 Feb 2024 Marie McDonald Buy 145 $41,180
Conversion of securities.
16 Feb 2024 Carolyn Hewson Exercise 193 $54,812
Conversion of securities. 193 Rights
16 Feb 2024 Alison Watkins Exercise 169 $47,996
Conversion of securities. 169 Rights
16 Feb 2024 Duncan Maskell Buy 339 $96,276
Conversion of securities.
16 Feb 2024 Robert Cuthbertson Buy 145 $41,180
Conversion of securities.
16 Feb 2024 Megan Clark Exercise 145 $41,180
Conversion of securities. 145 Rights
16 Feb 2024 Brian McNamee Exercise 343 $97,412
Conversion of securities. 343 Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Carolyn Judith Hewson Non-Executive Director Dec 2019
Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has financial markets, risk management and investment management expertise. She has non-executive experience in several sectors bringing experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture, and the changing external environment. She is Chair of the Corporate Governance Committee, Member of the Risk Management Committee and Human Resources Committee.
Ms Alison Mary Watkins Non-Executive Director Aug 2021
Ms Watkins brings experience to the Board through the executive and non executive roles she has held across industries, including manufacturing, agriculture, consumer goods, retail and financial services. She is Chair of Risk Management Committee and Member of the Human Resources Committee.
Dr Brian Anthony McNamee Non-Executive DirectorNon-Executive Chairman Jan 1990
Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy and creating shareholder value. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued several private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is Member of the Innovation and Development Committee and Corporate Governance.
Dr Robert Andrew Cuthbertson Non-Executive Director Oct 2018
Dr Cuthbertson has over 35 years of experience in medical research and biotech development with biopharmaceutical companies and medical organisations. He also has non-executive director experience. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is Chair of the Innovation and Development Committee and Member of the Corporate Governance Committee.
Ms Marie Elizabeth McDonald Non-Executive Director Aug 2013
Ms McDonald has executive and non-executive experience in several sectors including law, medical research, manufacturing, and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years of experience in the legal sector. She was previously a Partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She is member of the Risk Management Committee and Human Resources Committee.
Ms Samantha (Sam) Louise Lewis Non-Executive Director Jan 2024
Ms Lewis Ms Lewis is a non-executive director serving on boards of ASX 100 companies since 2014. Ms Lewis has experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. Prior to becoming a Non-executive Director, Ms Lewis spent 24 years with Deloitte, including 14 years as a Partner. In that role, she acted as lead auditor of several Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs, and debt/equity raisings. Ms Lewis has experience working with companies in the manufacturing, retail, and industrial sectors. She is member of the Risk Management Committee.
Dr Megan Elizabeth Clark Non-Executive Director Feb 2016
Dr Clark has executive and non-executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education, and mining. Through her roles, Dr Clark brings a strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. In 2014, Dr Clark was made a Companion of the Order of Australia for eminent service to scientific research and development. He is Chair of the Human Resources Committee, and Member of the Corporate Governance and Innovation and Development Committee.
Dr Paul McKenzie Chief Operating OfficerExecutive DirectorChief Executive OfficerManaging Director Dec 2022
Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing organisations through growth and transformation. He changed CSL's global end to end operations, advanced CSL Seqirus differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb, and Merck. He is also Member of the Innovation and Development Committee.
Ms Elaine Sorg Non-Executive Director Sep 2024
Ms Sorg has more than 35 years experience as a senior executive with pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVies US commercial operations. She is currently on the Deans Advisory Council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a Senior Advisor at the Boston Consulting Group, where she advises global health care clients on business-critical strategies and decisions.
Dr Brian Daniels Non-Executive Director Dec 2024
--
Ms Fiona Mead Company SecretaryHead of Group Governance Jun 2018
-
Kate Priestman Chief Corporate & External Affairs Officer
-
Joy Linton Chief Financial Officer
-
Roanne Parry Chief Human Resources Officer
-
Fiona Mead Company SecretaryHead of Group Governance
-
Ken Lim Executive Vice President and Chief Strategy Officer
-
Mark Hill Executive Vice President Chief Digital Information Officer
-
Andy Schmeltz Executive Vice President CSL Behring
-
Bill Mezzanotte Executive Vice President Head of Research & Development
-
Greg Boss Executive Vice President Legal and CSL Group General Counsel
-
Dave Ross Senior Vice President and General Manager CSL Seqirus
-
Herve Gisserot Senior Vice President and General Manager CSL Vifor
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 162,829,983 33.69%
P Morgan Nominees Australia Pty Limited 86,779,316 17.96%
Citicorp Nominees Pty Limited 46,160,603 9.55%
Bnp Paribas Nominees Pty Ltd <Agency Lending A/C> 11,290,713 2.34%
National Nominees Limited 8,358,823 1.73%
BNP Paribas Noms Pty Ltd 7,126,947 1.47%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 5,206,440 1.08%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,491,236 0.72%
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 2,862,019 0.59%
Netwealth Investments Limited <Wrap Services A/C> 2,822,828 0.58%
Australian Foundation Investment Company Limited 2,239,500 0.46%
Solium Nominees (Australia) Pty Ltd <Allocated A/C> 1,682,180 0.35%
Custodial Services Limited <Beneficiaries Holding A/C> 1,611,222 0.33%
Argo Investments Limited 1,341,509 0.28%
Mutual Trust Pty Ltd 1,051,510 0.22%
BNP Paribas Noms (Nz) Ltd 1,024,918 0.22%
Solium Nominees (Australia) Pty Ltd <Vsa A/C> 796,200 0.16%
D W S Nominees Pty Ltd 793,208 0.17%
IOOF Investment Services Limited <Ioof Idps A/C> 687,223 0.14%
Ioof Investment Services Limited <Ips Superfund A/C> 669,103 0.14%

Profile

since

Note